9月29日晚，迪哲医药（688192.SH）公告称，公司已于近期收到阿斯利康就舒沃哲（舒沃替尼）全球授权支付的6亿美元首付款。该笔款项的到账，标志着这款由迪哲医药自主研发的口服EGFR抑制剂全球商业化进程进入实质阶段。 根据公告，迪哲医药此前与阿斯利康签署《许可协议》，授予阿斯利康在全球范围内独家开发、商业化舒沃哲的权利。协议于2026年8月31日正式生效。除6亿美元一次性、不可返还的首付款外，...
Source Link9月29日晚，迪哲医药（688192.SH）公告称，公司已于近期收到阿斯利康就舒沃哲（舒沃替尼）全球授权支付的6亿美元首付款。该笔款项的到账，标志着这款由迪哲医药自主研发的口服EGFR抑制剂全球商业化进程进入实质阶段。 根据公告，迪哲医药此前与阿斯利康签署《许可协议》，授予阿斯利康在全球范围内独家开发、商业化舒沃哲的权利。协议于2026年8月31日正式生效。除6亿美元一次性、不可返还的首付款外，...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.